GB979389A - Pharmaceutical compositions containing naphthalene derivatives - Google Patents

Abstract

Pharmaceutical compositions suitable for the treatment of coronary artery disease comprise as active ingredient at least one compound of the formula <FORM:0979389/A5-A6/1> wherein R1 and R2, which may be the same or different, stand for hydrogen or alkyl radicals and R3 stands for an alkyl or aralkyl radical, and wherein the naphthalene nucleus may optionally bear one or more additional substituents, or a pharmaceutically acceptable salt thereof, in admixture with an inert pharmaceutically acceptable diluent or carrier. As optional substituents in the naphthalene nucleus there are specified halogen atoms, hydroxyl groups, alkyl radicals of not more than 4 carbon atoms and alkoxy radicals of not more than 4 carbon atoms. The pharmaceutically acceptable salts may be those of hydrochloric, hydrobromic, phosphoric, sulphuric, oxalic, lactic, tartaric, acetic, salicylic and citric acids. Specified active ingredients are 1-(1-naphthyl)-2 - isopropylaminoethanol, 1 - (1 - naphthyl) - 2-isobutylaminoethanol, 1 - (1 - naphthyl) - 2 - N-isopropyl - N - methylaminoethanol, 1 - (4 - hydroxy - 1 - naphthyl) - 2 - methylaminoethanol, 1 - (4 - chloro - 1 - naphthyl) - 2 - isopropylaminoethanol, 1 - (4 - methyl - 1 - naphthyl) - 2 - isopropylaminoethanol and 1-(1-naphthyl) - 2 - methylaminopropan - 1 - ol, and oxalate salts of some of these compounds. The compositions may take the form of tablets, capsules, sterile aqueous or oily solutions, aqueous or oily suspensions, emulsions, or dispersible powders. The usual optional ingredients such as sweetening and flavouring agents, suspending or thickening agents, surface-active agents, preservatives and fatty oils may also be included in the compositions. According to the Provisional Specification, R1 and R2 in the formula given above represent hydrogen or hydrocarbon radicals, and R3 represents a hydrocarbon radical.